Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

Running, not enrolling

Conditions studied: Acute Kidney Injury, Fluid Overload

In brief

The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription. A minimum of 10 centers in the United States, that have been trained on the use of the Carpediem™ system, will be invited to participate in the study. After obtaining institutional review board approval and written informed consent from a parent or legally authorized representative (LAR), data from all subjects treated with the Carpediem™ system will be included in the study. A minimum of 35 subjects will be enrolled and sites may be asked to screen and enroll patients for the study for up to 36 months. Status of subjects discharged from hospital will be collected at 30- and-90 days following hospital discharge by phone interviews in accordance to local standard of care practices, review of in-hospital records or in-clinic visit, as available.

Key facts

Study ID: NCT04608149
Run by: Mozarc Medical US LLC
People needed: 36
Starts: 2021-01-20
Expected to finish: 2026-04-01
Last updated by the study team: 2026-04-01

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Parent or LAR has signed information consent
Subject weighs between 2.5-10 kg (or 5.5-22 lbs)
Subject is receiving medical care in an intensive care unit
Parental or LAR consent to receive full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours
Subject has a clinical diagnosis of acute kidney injury per Kidney Disease Improving Global Outcomes (KDIGO) criteria or fluid overload requiring CRRT

You may not qualify if…

Subject is not expected to survive 72 hours due to an irreversible medical condition, in the opinion of the investigator
Subject has irreversible brain damage, in the opinion of the investigator
Subject is intolerant to anticoagulation, as documented in the medical record
Subject has a Do Not Attempt Resuscitate (DNAR), Allow Natural Death (AND), withdrawal of care or similar order, or anticipated change in status, in the opinion of the investigator, within the next 7 days
Subject has pre-existing end-stage renal disease or pre-existing, advanced chronic kidney disease, defined as an estimated Glomerular Filtration Rate (eGRF) < 30 ml/min/1.73m2
Subject is currently or has chronically been treated with a circulatory support device (i.e., left ventricular assist device (LVAD)) other than ECMO
Subject has had prior CRRT treatments using the Carpediem™ system
Subject is enrolled in clinical trials or being treated with other investigational therapeutic devices or products for acute kidney injury or fluid overload
Subject has any other medical condition that may confound the study objectives, in the opinion of the investigator

Where it is running

University of Iowa Healthcare — Iowa City, Iowa, United States
Mayo Clinic — Rochester, Minnesota, United States
Golisano Children's Hospital — Rochester, New York, United States
Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
Texas Children's Hospital — Houston, Texas, United States
Seattle Children's — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.